Change in neurobehavioral manifestations · children and adults with Smith‐Lemli‐Opitz syndrome
1 finding from 1 review
Statin‐related adverse events · children and adults with Smith‐Lemli‐Opitz syndrome
It is very uncertain whether statins with cholesterol supplementation changes statin‐related adverse events compared with cholesterol supplementation only (very low certainty).
1 finding from 1 review
Growth · children and adults with Smith‐Lemli‐Opitz syndrome
1 finding from 1 review
Changes in biochemical markers plasma dehydrocholesterol levels (mM); plasma cholesterol levels (mM); plasma 7DHC levels (mM); plasma CoQ levels (uM); CSF cholesterol levels (ug/mL); CSF dehydrocholesterol levels (ug/mL) · children and adults with Smith‐Lemli‐Opitz syndrome
1 finding from 1 review
QoL · children and adults with Smith‐Lemli‐Opitz syndrome
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality · participants with improving outcomes during and after noncardiac vascular surgery.
Perioperative statins showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
All cardiovascular death · participants with improving outcomes during and after noncardiac vascular surgery.
Perioperative statins showed no clear difference in death from cardiovascular causes compared with placebo or no treatment (low certainty).
1 finding from 1 review
Non‐fatal MI · participants with improving outcomes during and after noncardiac vascular surgery.
Perioperative statins showed no clear difference in myocardial infarction (non‐fatal) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Stroke/TIA (non‐fatal) · participants with improving outcomes during and after noncardiac vascular surgery.
Perioperative statins showed no clear difference in stroke/TIA (non‐fatal) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Participant‐reported outcomes－not measured · participants with improving outcomes during and after noncardiac vascular surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse muscle effects · participants with improving outcomes during and after noncardiac vascular surgery.
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Drug expenditure · Patients taking statins
1 finding from 1 review
no estimate extracted
Studies not reported
Very low